{
    "code": 0,
    "data": [
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings Call Transcript for meeting held on 22 January 2026",
            "news_id": "885074c4-762f-445d-bb07-cb873d0aaade",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=34b1a767-1439-465b-924c-69b545d3a86b.pdf",
            "news_date": "2026-01-27 15:12:22",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "In continuation to our earlier intimation dated January 15 2026 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 the audio recording of the Jagsonpal Pharmaceuticals Limited Q3 FY26 Earnings Conference Call held on January 22 2026 at 5:00 P.M. for discussion of Q3 FY26 Financial Results is available on the Companys website at below link: https://www.jagsonpal.com/investor-relations/earning-calls.\r\nWe request you to take the above on record.",
            "news_id": "49b102df-1230-4ea5-9d26-d2a66ebea9da",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=493a7558-6ba4-4844-ac7d-e4c1be128755.pdf",
            "news_date": "2026-01-22 18:55:54",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Press release and investor presentation for the quarter and nine months ended December 31 2025",
            "news_id": "1f5f337a-bd3f-4eb1-90db-94acbe1c805a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=50f29d76-4e8a-446b-a571-60c71bae4969.pdf",
            "news_date": "2026-01-21 19:12:18",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On January 21 2026 Along With Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025",
            "news_body": "Pursuant to Regulation 33 of SEBI (LODR) 2015 we would like to inform you that the board of directors at its meeting held today inter-alia considered and approved the unaudited financial results for the quarter and nine months ended December 31 2025",
            "news_id": "9d377561-4fdb-47ca-84fb-5ed7b2c7d281",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ab3a9cd6-ad17-4e78-85c8-d56f4e664a8e.pdf",
            "news_date": "2026-01-21 17:33:30",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (LODR) Regulations 2015 Please find enclosed transcript for the jagsonpal pharmaceuticals Limited Q2 FY 2026 earnings call held on November 04 2025 at 2:00 P.M for discussion of Q2 FY26 Financial Results.",
            "news_id": "80cfe445-5a01-4c9b-bcc7-7b51ae0ca787",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=344040a4-306a-4bdd-a0cd-5345a0ea1795.pdf",
            "news_date": "2025-11-07 15:16:17",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 the audio recording of the Jagsonpal Pharmaceuticals Limited Q2 FY26 Earnings Conference Call held on November 04 2025 at 2:00 P.M.",
            "news_id": "83f0b935-c1bc-4964-b52a-ea24e1b95d93",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a0c50c5c-8567-451f-8344-fb186300c3a4.pdf",
            "news_date": "2025-11-04 17:09:41",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Press Release and Investor Presentation on Un- Audited Financial Results for the quarter and half year ended September 30 2025",
            "news_id": "aa464732-0689-46c4-ae0f-b022f1244ac1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=69192bd4-c5b6-4b1f-810e-6e723d9822a9.pdf",
            "news_date": "2025-11-03 19:00:14",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025",
            "news_body": "Pursuant to regulation 30 & Regulation 33 of SEBI (LODR) Regulations 2015 Please find enclosed the Unaudited Financial results along with its Limited review report of the Company for the quarter and half year ended September 30 2025.",
            "news_id": "b114b39a-1f9c-42f8-b427-59b9306ddfd8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1d93ae0a-c6fc-4dd9-88fb-76b017a19a39.pdf",
            "news_date": "2025-11-03 17:28:18",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings call Transcript for Jagsonpal Pharmaceuticals Limited Q1FY 26 Earnings Conference call held on July 28 2025 at 3:00 P.M.",
            "news_id": "29846c10-f64e-446e-8db0-a77ec8f8dff7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2ab02c33-adcb-4c3e-b4c8-ec9f0a89a8d2.pdf",
            "news_date": "2025-07-31 12:06:30",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio Recording of Jagsonpal Pharmaceuticals Limited Q1 FY26 Earnings Conference Call on July 28 2025 at 3:00 P.M",
            "news_id": "cfc3f7b4-347f-4124-a507-ab0c14883742",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e11c785d-3fbf-4e18-898f-4c393bea1cf6.pdf",
            "news_date": "2025-07-28 17:46:06",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Revised Investors Presentation for financial Results for the quarter ended June 30 2025",
            "news_id": "407d1222-5d08-4a87-b65e-127c0528d6c8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a28bb2c3-a0a4-47c5-80f0-ce2bf8f80577.pdf",
            "news_date": "2025-07-26 17:05:44",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Press Release for Unaudited Financial Results for the quarter ended June 30 2025",
            "news_id": "83ded6d8-8f19-4409-9011-0353440f2dc4",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c3721c27-a575-4b08-b2cf-52809821b11e.pdf",
            "news_date": "2025-07-26 13:45:18",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results- Financial Results For The Quarter Ended June 30 2025",
            "news_body": "Unaudited Financial results for the quarter ended June 30 2025",
            "news_id": "681ad9c6-0a4e-4329-b100-abc8343eb964",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=79a7aa7c-fb7f-47ff-8789-df4854540e9c.pdf",
            "news_date": "2025-07-26 13:00:49",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings Call Transcript for Jagsonpal Pharmaceuticals Limited Q4FY25 Earnings Conference Call held on May 7 2025",
            "news_id": "3a14d135-f88c-4556-92a9-fd237c300095",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f538ec5d-ba34-4c69-aec7-b824b9c0c2f1.pdf",
            "news_date": "2025-05-13 15:12:36",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio Recording of Jagsonpal Pharmaceuticals Limited Q4 FY25 Earnings Conference Call on May 07 2025 at 4:00 P.M.",
            "news_id": "7c1fe01a-4f6d-4545-8579-27dd459781c5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=728b8896-d5e5-4fb3-9d6f-1d6732731aba.pdf",
            "news_date": "2025-05-07 18:40:56",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investors Presentation for the quarter and year ended March 31 2025",
            "news_id": "0a700ba9-581a-42e3-a082-a43e757b3e59",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9ae9ac29-12b4-46d4-a15e-11d759f2c5b4.pdf",
            "news_date": "2025-05-06 20:31:26",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited (Standalone) Financial Results For The Year Ended March 31 2025",
            "news_body": "Audited (Standalone) Financial Results for the year ended March 31 2025",
            "news_id": "c30da9d8-0547-4361-affa-463091c26951",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=76e0e5f4-4cad-43a8-81af-056319590215.pdf",
            "news_date": "2025-05-06 19:28:31",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Reg. 30 of SEBI (LODR) Reg. 2015 please find enclosed transcript of earning call of Jagsonpal Pharmaceuticals Limited held on January 23 2025 at 10:00 AM.\r\n",
            "news_id": "99da8eb3-4f85-48f7-ac70-9c1054d0a7c9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9f4a76e6-5cad-436f-b67c-b10c9dbb5a0c.pdf",
            "news_date": "2025-01-29 13:09:20",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On January 22 2025 To Consider And Approve The Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024",
            "news_body": "Please find enclosed the Unaudited Financial Results along with Limited Review Report issued by the Statutory Auditors of the Company for the quarter and nine months ended December 31 2024.",
            "news_id": "ee956a5a-9485-45f5-8f3a-79f842c7c9fb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d2729cf2-4565-4f88-9237-7bacd28ad3c6.pdf",
            "news_date": "2025-01-22 18:13:31",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Please find enclosed Transcript for the Jagsonpal Pharmaceuticals Limited Q2FY25 Earning Confrence Call held on October 24, 2024 at 11:00 AM for discussion of Q2FY25 & H1FY25 Financial Results.",
            "news_id": "d7219a1c-57c8-4e27-8d2d-6f98dad68453",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ef3c1c32-5168-43ec-a8ad-37e66505d06e.pdf",
            "news_date": "2024-10-29 17:09:22",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio Recording of Jagsonpal Pharmaceuticals Limited Q2 FY25 and H1 FY25 Earnings Conference Call on October 24, 2024",
            "news_id": "8587b175-2529-4eb7-84d3-130adb177975",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=de34dddc-f426-4706-94f4-98fc667977ec.pdf",
            "news_date": "2024-10-24 16:42:06",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "In continuation to earlier intimation dated October 23, 2024 Please find enclosed herewith revised investor presentation for quarter and half year ended September 30, 2024 due to inadvertent error in slide 20, and then same has been rectificed.",
            "news_id": "ff3f8348-833e-49c6-9c08-9965881f3f0d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ad92753b-e936-412c-86ed-a52086eaf606.pdf",
            "news_date": "2024-10-24 10:51:08",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On October 23, 2024 & Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements Regulations, 2015",
            "news_body": "Please find enclosed Unaudited financial result and limited review report for quarter and half year ended September 30, 2024",
            "news_id": "92535a38-e924-4f23-8a0c-cf5d64b76309",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b4c54404-69e7-4445-9d65-05db0dcc99c9.pdf",
            "news_date": "2024-10-23 18:05:20",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On August 07, 2024 Along With Unaudited Financial Results For The Quarter Ended June 30, 2024",
            "news_body": "Please find enclosed herewith Unaudited Financial Results along with limited review report for quarter ended June 30, 2024.",
            "news_id": "864d2cea-0a89-48fd-b5fe-4d5a13b15176",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e6d655ca-cea3-446d-b15f-bdb3e8dd3dd6.pdf",
            "news_date": "2024-08-07 18:42:12",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On May 20, 2024 Along With Audited (Standalone) Financial Results For The Quarter And Year Ended March 31, 2024",
            "news_body": "Please find enclosed Audited Financial Result for the year ended March 31, 2024 along with Indepedent Auditors Report",
            "news_id": "591e9d69-2ac2-463c-86e0-6be20b50e433",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1c06ece6-e90f-48a3-857d-d24f6f163c29.pdf",
            "news_date": "2024-05-20 19:19:54",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On February 02, 2024 Along With Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2023<BR>",
            "news_body": "Please find enclosed Unaudited Financial Results for Quarter and Nine Months ended December 31, 2023 along with limited review report  for the quarter and nine months ended December 31, 2023.",
            "news_id": "4b1626c3-d9df-4129-b199-c7b3de300db8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5d744640-063b-46ad-a53c-697ed0e781db.pdf",
            "news_date": "2024-02-02 17:24:02",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On November 03, 2023 Along With Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2023",
            "news_body": "Please enclose herewith quarterly and half yearly financial results with limited review report for the quarter and half year ended on September 30, 2023.",
            "news_id": "c9dacc4a-d35f-49e5-9431-bc3d8fb6e0a9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=51dbc89e-ca7a-4e02-a888-8d4b57239440.pdf",
            "news_date": "2023-11-03 13:58:08",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On August 02, 2023 Along With Unaudited Financial Results For The Quarter Ended June 30, 2023",
            "news_body": "Kindly find enclosed the Unaudited Financial Results for the quarter ended June 30, 2023 along with Limited Review Report",
            "news_id": "4c3c4b58-e96b-48c9-b77b-c0f4aa5d849a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=041671e3-7b53-443e-b3bc-cf247db6b531.pdf",
            "news_date": "2023-08-02 18:20:33",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On August 02, 2023 Along With Unaudited Financial Results For The Quarter Ended June 30, 2023",
            "news_body": "Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and<BR> Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we<BR> would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered<BR> and approved the Unaudited Financial Results for the quarter ended June 30, 2023. In this regard,<BR> kindly find enclosed the Unaudited Financial Results along with its Limited Review Report by the<BR> Statutory Auditors of the Company for the quarter ended June 30, 2023.",
            "news_id": "9ca177d9-dbe8-4a19-9afd-c809f13ae4d7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f247426b-8e3d-4f2a-a784-5f4378e3f36b.pdf",
            "news_date": "2023-08-02 18:16:40",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On May 23, 2023 Along With Audited (Standalone) Financial Results For The Quarter And Year Ended March 31, 2023",
            "news_body": "Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we<BR> would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered<BR> and approved the Audited (Standalone) Financial Results for the quarter and year ended March 31,<BR> 2023. In this regard, kindly find enclosed the following:<BR> 1. Audited (Standalone) Financial Results along with Independent Auditor's Review Report issued<BR> by the Statutory Auditors of the Company for the quarter and year ended March 31, 2023.<BR> 2. The Board recommended a dividend of Rs. 5/- per equity share for the financial year ended<BR> March 31, 2023.<BR> The Board Meeting commenced at 11:15 a.m. and concluded at 2:20 p.m.",
            "news_id": "83f12e7e-4506-4622-8c87-49ab55929cf5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8c2a6d2e-2353-4ddb-81a6-41a24b667eb9.pdf",
            "news_date": "2023-05-23 14:44:44",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On May 23, 2023 Along With Audited (Standalone) Financial Results For The Quarter And Year Ended March 31, 2023",
            "news_body": "Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and<BR> Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we<BR> would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered<BR> and approved the Audited (Standalone) Financial Results for the quarter and year ended March 31,<BR> 2023. In this regard, kindly find enclosed the following:<BR> 1. Audited (Standalone) Financial Results along with Independent Auditor's Review Report issued<BR> by the Statutory Auditors of the Company for the quarter and year ended March 31, 2023.<BR> 2. The Board recommended a dividend of Rs. 5/- per equity share for the financial year ended<BR> March 31, 2023.",
            "news_id": "c7017c1a-24cb-4342-bb1c-91bc4decd9db",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=52bc4ba4-8ef7-4d34-af1c-d9c826a985e0.pdf",
            "news_date": "2023-05-23 14:38:00",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results For The Quarter And Nine Months Ended 31St Dec, 2022.",
            "news_body": "Unaudited financial results quarter and nine months ended 31st dec, 2022.",
            "news_id": "fb692513-9a6e-4cad-b83b-dd9fc0a94048",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=50ddd45f-627a-46ed-991d-df42db26af73.pdf",
            "news_date": "2023-02-08 20:08:49",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transaction Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements Regulations, (Amendments) 2018.",
            "news_body": "Pursuant to Regulation 23(9) of the SEBI Listing Regulations, please find enclosed herewith disclosures of related party transactions on consolidated basis in the revised format, as prescribed under SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated 22 November 2021, for the half year ended commencing from 01 April, 2022 to 30 September, 2022.",
            "news_id": "d2869889-d63b-4975-b387-43fb23c8d2e5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ca141437-c15e-42ad-8597-eaad0a333686.pdf",
            "news_date": "2022-11-24 12:23:46",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For The Quarter And Half Year Ended 30 September, 2022.",
            "news_body": "Financial Results for the quarter and half year ended 30 September, 2022.",
            "news_id": "0d7055e2-ee85-46e7-baf6-1eaedc8b1701",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=69fa2eca-bb71-4f17-bc7a-6fe9be52e6be.pdf",
            "news_date": "2022-11-09 19:09:21",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for OUTCOME OF THE MEETING OF BOARD OF DIRECTORS OF JAGSONPAL PHARMACEUTICALS LIMITED HELD ON NOVEMBER 09TH, 2022.",
            "news_body": "OUTCOME OF THE MEETING OF BOARD OF DIRECTORS OF JAGSONPAL PHARMACEUTICALS LIMITED HELD ON NOVEMBER 09TH, 2022.",
            "news_id": "e6f4a91b-cb8d-463d-899b-aefb6b159d5e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f3a8d9da-e899-495e-8106-ca00158b0ecc.pdf",
            "news_date": "2022-11-09 19:04:33",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For The Quarter Ended 30.06.2022",
            "news_body": "Financial results for the quarter ended 30.06.2022 along with the press release and result presentation.",
            "news_id": "e35ce2ea-7e81-494b-ae81-923d1f02c4c5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e3e0e964-7c36-4310-b7c8-a91ab10cac80.pdf",
            "news_date": "2022-08-09 19:35:16",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions On Consolidated Basis For The Half Year Ended 31 March, 2022",
            "news_body": "Please find enclosed herewith disclosures of related party  transactions on consolidated basis, as prescribed under SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated 22nd November 2021, for the half year ended 31st March, 2022.",
            "news_id": "bdb95ef7-42e4-42ee-a847-10b3d696a935",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=283ea3ea-0cd8-479c-8543-de6eb316d6a3.pdf",
            "news_date": "2022-06-14 17:48:46",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For The Quarter And Financial Year Ended 31 March, 2022.",
            "news_body": "Audited Financial Results for the quarter and financial year ended 31 March, 2022.",
            "news_id": "35b4289e-5147-43ce-98ac-730ebdb707cc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9a77f879-fbbb-4030-a2c3-024733c29d84.pdf",
            "news_date": "2022-05-30 18:30:51",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor presentation",
            "news_id": "3ed81fd6-437c-4647-beaa-c7652c8154df",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4123fe62-8c6c-4e7a-b81f-92ff5d923e63.pdf",
            "news_date": "2022-02-21 23:50:56",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for OUTCOME OF THE MEETING OF BOARD OF DIRECTORS OF JAGSONPAL PHARMACEUTICALS LIMITED HELD ON FEBRUARY 11TH, 2022.",
            "news_body": "This is to intimate that the Board of Directors of the Company at their meeting held today, (i.e. Friday, the 11th Day of February, 2022), have inter alia, approved and taken on record the following:<BR> <BR> 1. The Un-audited Financial Results for the quarter and nine months ended 31st December, 2021; <BR> 2. Limited Review Report on the Un-audited Financial Results for the said quarter;<BR> 3. Took note of Resignation of Mr. Sanjiv Kumar Dudeja from the position of Chief Financial Officer of the Company;<BR> 4. Appointment of Mr. S.V. Subha Rao as the Chief Financial Officer with effect from 11th February, 2022;<BR> 5. Other agenda items. <BR>",
            "news_id": "1a777ff9-89e8-4e75-ad45-9fc74e27aa0d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f4ef662f-c8ff-47d5-9cd9-18df17596207.pdf",
            "news_date": "2022-02-11 13:27:03",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Under Reg 23(9) Of SEBI (LODR), 2015.",
            "news_body": "Disclosure under Reg 23(9) of SEBI (LODR), 2015.",
            "news_id": "369f811c-b310-4f72-ba01-fda8bd6a7f83",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c4dcd85-ec72-4d73-9f37-61dc8c5f66d4.pdf",
            "news_date": "2021-11-17 17:06:39",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Standalone Un-Audited Financial Results Of The Company For The Quarter And Half Year Ended 30Th September, 2021;",
            "news_body": "Standalone Un-Audited Financial Results of the Company for the quarter and half year ended 30th September, 2021;",
            "news_id": "d6141f58-1bb8-4501-8334-fcba6ef5840a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e9f1429e-fd46-4bf3-b653-7feab53ee9c6.pdf",
            "news_date": "2021-10-19 17:25:57",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for OUTCOME OF THE MEETING OF BOARD OF DIRECTORS OF JAGSONPAL PHARMACEUTICALS LIMITED HELD ON OCTOBER 19TH, 2021",
            "news_body": "Board has approved the Unaudited Financial Results for the quarter and half year ended 30 September, 2021 . Further, the Board has also declared and approved an Interim Dividend @ 80% per Equity Shares of face value of Rs. 5/- each, i.e.  Rs. 4/- per Equity Share. <BR> The Interim Dividend shall be paid to the equity shareholders of the Company, whose names appear on the Register of Members of the Company or in the records of the Depositories as beneficial owners of the shares as on Monday, November 01, 2021 which is the Record Date fixed for the purpose.<BR> The book closure will be from 02nd November, 2021 to 3rd November, 2021 for the purpose of Interim Dividend.",
            "news_id": "1503fe11-c4f9-42d2-bfd6-826e301a12cc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a01df083-c7b5-4a7e-8a03-3de69647e337.pdf",
            "news_date": "2021-10-19 17:17:02",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of The Board Meeting Held On 13 August, 2021.",
            "news_body": "Outcome of the Board meeting held on 13 August, 2021.<BR> The meeting was concluded at 1855 hours.",
            "news_id": "f9d04a1f-86ad-43c4-b6e0-344a6b76c7e3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6ff5d6fc-0c3f-4c1b-b820-0ac3b0086df5.pdf",
            "news_date": "2021-08-13 19:11:17",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transaction Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements Regulations, (Amendments) 2018 For The Financial Year Ended 31 March, 2021.",
            "news_body": "Pursuant to Regulation 23 (9) of the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018, please find enclosed disclosure of Related Party Transaction, in the format specified in the Accounting Standard for the financial year ended March 31, 2021.<BR> <BR> This is for your information and records.",
            "news_id": "c657f94d-0023-46b1-b28e-fe8ad4c47bfb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ea7be2e1-f813-4144-aa8a-5f924c0a80fe.pdf",
            "news_date": "2021-07-29 12:19:57",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of The Board Meeting",
            "news_body": "Outcome of the Board Meeting",
            "news_id": "cf51021d-526a-4730-8714-1ff0f804084a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1e3f039b-22a0-449c-9801-8dc346db072b.pdf",
            "news_date": "2021-06-30 16:18:20",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For The Quarter And Year Ended 31.03.2021.",
            "news_body": "OUTCOME OF THE MEETING OF BOARD OF DIRECTORS OF JAGSONPAL PHARMACEUTICALS LIMITED HELD ON JUNE 30TH, 2021.",
            "news_id": "ab748b4d-4fdc-4301-9c35-494f1c8324fc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9fdb74ae-e7d6-467e-ad4d-63c00d35362a.pdf",
            "news_date": "2021-06-30 16:12:42",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For The Quarter Ended 31 December, 2020.",
            "news_body": "Financial Results for the quarter ended 31 December, 2020.",
            "news_id": "e62e72fa-fbb5-46e1-a8d3-4a8af2dc3abb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=37fcc7fd-07c0-4e78-9de4-4d85fdc3387b.pdf",
            "news_date": "2021-02-12 14:48:11",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        }
    ],
    "remarks": ""
}